Coronary interventions Thromboresistance and functional healing in the COBRA PzF stent versus competitor DES: implications for dual antiplatelet therapy Jinnouchi H, Mori H, Cheng Q, Kutyna M, Torii S, Sakamoto A, Guo L, Acampado E, Gupta A, Kolodgie F, Virmani R, Finn A July 19, 2019 | 10.4244/EIJ-D-18-00740
Stents and scaffolds Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents Torii S, Cheng Q, Mori H, Lipinski M, Acampado E, Perkins L, Hossainy S, Pacetti S, Kolodgie F, Virmani R, Finn A March 20, 2019 | 10.4244/EIJ-D-17-00728
Coronary interventions Pathological aspects of bioresorbable stent implantation Sanchez O, Yahagi K, Byrne R, Mori H, Zarpak R, Wittchow E, Foin N, Virmani R, Joner M May 19, 2015 | 10.4244/EIJV11SVA39
New issue Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue (Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right)) December 6, 2019
JAA This week's JAA's: EXTREME Study, Stent Optimization, Trifurcation disease and more December 3, 2019
Trials Book New update! Discover 17 new trials (The Trials book is supported by Biotronik) October 29, 2019
Editorial 2019 – A leap year for valvular heart disease (Course directors PCR London Valves 2019) November 15, 2019